1. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences – FBMS – College of Medicine, Bayero University, Kano, Kano, Nigeria.
2. Department of Community Medicine, Faculty of Clinical Sciences, Bayero University, Kano, Kano, Nigeria.
3. Department of Medical Laboratory Science, Faculty of Allied Health Sciences – FAHS – Bayero University, Kano, Kano, Nigeria.
4. Kano State TB and Leprosy Control Program, Kano State Ministry of Health, Kano, Nigeria.
5. Kano State Infectious Disease Hospital, Kano State Ministry of Health, Kano, Nigeria.
6. Pharmacotherapeutics Lab, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Recebido: 5 setembro 2023.
Aprovado: 1 novembro 2023.
Trabalho realizado no Kano State Infectious Disease Hospital, Kano State Ministry of Health, Kano, Nigeria.
Endereço para correspondência:
Ibrahim Mohammed Badamasi. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences – FBMS – College of Medicine, Bayero University, Kano, Kano State, Kano, Nigeria.
Tel.: 08037024135. E-mail: bimohammed.ana@buk.edu.ng
Johnson Stanslas. Pharmacotherapeutics Lab, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Tel.: +60 122670497. E-mail: jstanslas@yahoo.co.uk
Apoio financeiro: Este estudo recebeu apoio financeiro do Nigerian Tertiary Education Trust Fund (Fundo Fiduciário de Ensino Superior da Nigéria).